Evolutionary Dynamics Between Phages and Bacteria As a Possible Approach for Designing Effective Phage Therapies Against Antibiotic-Resistant Bacteria
Overview
Authors
Affiliations
With the increasing global threat of antibiotic resistance, there is an urgent need to develop new effective therapies to tackle antibiotic-resistant bacterial infections. Bacteriophage therapy is considered as a possible alternative over antibiotics to treat antibiotic-resistant bacteria. However, bacteria can evolve resistance towards bacteriophages through antiphage defense mechanisms, which is a major limitation of phage therapy. The antiphage mechanisms target the phage life cycle, including adsorption, the injection of DNA, synthesis, the assembly of phage particles, and the release of progeny virions. The non-specific bacterial defense mechanisms include adsorption inhibition, superinfection exclusion, restriction-modification, and abortive infection systems. The antiphage defense mechanism includes a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) system. At the same time, phages can execute a counterstrategy against antiphage defense mechanisms. However, the antibiotic susceptibility and antibiotic resistance in bacteriophage-resistant bacteria still remain unclear in terms of evolutionary trade-offs and trade-ups between phages and bacteria. Since phage resistance has been a major barrier in phage therapy, the trade-offs can be a possible approach to design effective bacteriophage-mediated intervention strategies. Specifically, the trade-offs between phage resistance and antibiotic resistance can be used as therapeutic models for promoting antibiotic susceptibility and reducing virulence traits, known as bacteriophage steering or evolutionary medicine. Therefore, this review highlights the synergistic application of bacteriophages and antibiotics in association with the pleiotropic trade-offs of bacteriophage resistance.
Karnwal A, Jassim A, Mohammed A, Al-Tawaha A, Selvaraj M, Malik T Front Microbiol. 2025; 16:1517772.
PMID: 40066274 PMC: 11891257. DOI: 10.3389/fmicb.2025.1517772.
Ranta K, Skurnik M, Kiljunen S Virol J. 2025; 22(1):55.
PMID: 40033410 PMC: 11877940. DOI: 10.1186/s12985-025-02679-w.
Phage therapy could be key to conquering persistent bacterial lung infections in children.
Sithu Shein A, Hongsing P, Khatib A, Phattharapornjaroen P, Miyanaga K, Cui L NPJ Antimicrob Resist. 2025; 2(1):31.
PMID: 39843534 PMC: 11721074. DOI: 10.1038/s44259-024-00045-4.
The Combination of Phage Therapy and β-Lactam Antibiotics for the Effective Treatment of Infections.
Moryl M, Szychowska P, Dziag J, Rozalski A, Torzewska A Int J Mol Sci. 2025; 26(1.
PMID: 39795870 PMC: 11719584. DOI: 10.3390/ijms26010011.
Palma M, Qi B Infect Dis Rep. 2024; 16(6):1127-1181.
PMID: 39728014 PMC: 11675988. DOI: 10.3390/idr16060092.